The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bayer; Genzyme; Heron; Regeneron; Squibb
Speakers' Bureau - Genzyme; Regeneron; Squibb
Research Funding - Novartis (Inst); Regeneron (Inst)
Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)
 
Howard Safran
No Relationships to Disclose
 
J. Thaddeus Thaddeus Beck
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); DSi (Inst); Lilly (Inst); Nektar (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Panos Savvides
No Relationships to Disclose
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Speakers' Bureau - BMS; Lilly; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Yujie Zhao
Employment - Mayo Clinic; Mayo Clinic
Honoraria - Coherus Biosciences; Lilly
Consulting or Advisory Role - Coherus Biosciences; Lilly
Research Funding - Alpine Immune Sciences (Inst); Incyte (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology; Pfizer (Inst); Zai Lab
 
James L. Abbruzzese
Stock and Other Ownership Interests - Bessor Pharma; Moleculin Biotech
Honoraria - Fujifilm; Pancreatic Cancer Action Network; Sun Pharma
Consulting or Advisory Role - Bessor Pharma; Fujifilm; Lucence Diagnostics ; Moleculin Biotech; Pancreatic Cancer Action network; Sun Biopharma
Research Funding - Amgen; Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Lucence Diagnostics ; Pancreatic Cancer UK
 
Jeffrey P. Ward
Employment - Millipore (I); Pfizer (I)
Consulting or Advisory Role - Guidepoint Inc; Novocure; Takeda
Research Funding - AstraZeneca (Inst); Genmab (Inst); Harpoon therapeutics (Inst); Instil Bio (Inst); Novocure (Inst); Pfizer (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Halozyme
 
Saravut John Weroha
Research Funding - Genentech; KIYATEC; Novartis; Tesaro
Patents, Royalties, Other Intellectual Property - Kiyatec; Mayo Clinic Ventures Ovarian Cancer PDX Models
Travel, Accommodations, Expenses - Merck
(OPTIONAL) Uncompensated Relationships - KIYATEC
 
Loleta D. Harris
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Sean Kent
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
William Pierceall
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Athanasia Skoura
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jenny Zheng
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kenneth Alan Kern
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jacob Stephen Thomas
No Relationships to Disclose
 
Rafael Santana-Davila
Consulting or Advisory Role - AstraZeneca; EMD Serono; Mirati Therapeutics
Research Funding - ALX Oncology (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)